Press Releases Nkarta, Inc.

Equities

NKTX

US65487U1088

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
5.91 ^USD	+0.85%		+7.45%	-10.45%

06-27	Nkarta Initiates Trial of Cell Therapy to Treat Lupus Nephritis; FDA Clears Second Application	MT
06-27	Nkarta, Inc. Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications	06-27	AQ
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors	06-13	AQ
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights	05-09	AQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors	04-08	BU
Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors	04-05	BU
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors	04-05	BU
Nkarta to Participate in Upcoming Investor Conferences	04-03	AQ
Nkarta Announces Pricing of $240 Million Underwritten Offering	03-25	AQ
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights	03-21	AQ
Nkarta to Participate in Upcoming Investor Conferences	02-28	AQ
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition	12-10	AQ
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights	11-09	AQ
Nkarta to Participate at Upcoming Investor Conferences	11-07	AQ
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer Cell Therapy in Lupus Nephritis	18/10/23	AQ
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis	17/10/23	AQ
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures	16/10/23	AQ
Rezo Therapeutics Appoints Nadir Mahmood, Ph.D., as Chief Executive Officer	21/09/23	AQ
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights	10/08/23	AQ
Nkarta to Participate at Upcoming Investor Conference	03/08/23	AQ
Nkarta Appoints Alyssa Levin Chief Financial and Business Officer	05/07/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Nkarta, Inc.

Equities

NKTX

US65487U1088

Press Releases

Filters